Companies
BeiGene
aggressively developing and commercializing original oncology biologics for both domestic and international markets.
- Country
- China
- Ticker
- BGNE
oncology
cn
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2010 (2010) | businesswire.com · sec.gov |
| Headcount | 11,000+ employees worldwide (2024-12-31) | ir.beonemedicines.com · sec.gov |
| Revenue | $3.81 billion USD for full year 2024 (2024-12-31) | ir-api.eqs.com · last10k.com |
| Production site | Guangzhou, China (39-acre site); Suzhou, China (12.4-acre site); Hopewell, New Jersey, US (42-acre site) (2024-11-01) | beonemedicines.com |
| Capacity | Guangzhou: 65,000L biologics (expandable to 200,000L), 600M OSD; Suzhou: 300M tablet & 300M capsule, 1kL biologics; Hopewell: 8,000L biologics (expandable to 16,000L) (2024-11-01) | beonemedicines.com |
| Certification | GMP standards (US FDA, EMA, TGA, China NMPA, ANVISA, etc.) (2024-11-01) | beonemedicines.com |
| Regulatory approval | 30+ approvals and inspections including US FDA, EMA, and China NMPA; medicines approved in 70+ markets (2024-12-31) | beonemedicines.com · ir.beonemedicines.com · businesswire.com |
Independent sources: beonemedicines.com · businesswire.com · ir-api.eqs.com · ir.beonemedicines.com · last10k.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| PROTACs (targeted protein degradation) | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.